14,388 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Aurora Private Wealth Inc.

Aurora Private Wealth Inc. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,388 shares of the medical research company's stock, valued at approximately $4,483,000. Amgen comprises approximately 1.1% of Aurora Private Wealth Inc.'s portfolio, making the stock its 23rd largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pinney & Scofield Inc. acquired a new stake in shares of Amgen during the fourth quarter valued at about $26,000. First Pacific Financial raised its holdings in Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after buying an additional 67 shares during the last quarter. Ritter Daniher Financial Advisory LLC DE raised its holdings in Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new position in Amgen in the 4th quarter valued at approximately $34,000. Finally, Atala Financial Inc bought a new position in Amgen in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Up 0.5%

Amgen stock traded up $1.40 during trading on Friday, hitting $298.25. 1,518,529 shares of the company were exchanged, compared to its average volume of 2,842,825. The business's 50 day moving average is $282.12 and its 200 day moving average is $286.57. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a market capitalization of $160.37 billion, a P/E ratio of 27.21, a PEG ratio of 2.70 and a beta of 0.49. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the prior year, the company posted $3.96 earnings per share. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares of the company's stock, valued at $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.76% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. William Blair reissued an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. UBS Group reissued a "neutral" rating and set a $315.00 target price (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Piper Sandler restated an "overweight" rating and issued a $328.00 price target on shares of Amgen in a research report on Friday, June 27th. Finally, Mizuho increased their price objective on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Amgen has a consensus rating of "Hold" and a consensus price target of $307.82.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.